UnitedHealthcare limits Aduhelm for all health plans: ‘unproven and not medically necessary’ 

(By Jakob Emerson for Becker’s Hospital Review)

UnitedHealthcare plans will only pay for the controversial Alzheimer’s drug Aduhelm for patients in clinical trials who have received prior authorization, according to a medical policy update filed May 1. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org